Introduction

Bigatab 90 mg (Brigatinib) Tablet is a next-generation tyrosine kinase inhibitor (TKI) designed for ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). Manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified leader in oncology therapeutics, and supplied globally by Onco Solution, this advanced medication targets resistant mutations to delay disease progression. With its unique ability to inhibit multiple kinases—including ALK, ROS1, IGF-1R, and FLT-3—Bigatab 90 mg (Brigatinib) Tablet offers renewed hope for patients with advanced NSCLC.

Key Benefits & Mechanism of Action

Bigatab 90 mg (Brigatinib) Tablet is a potent kinase inhibitor with clinically proven efficacy against ALK and ROS1 fusion proteins. Its mechanism includes:

1. ALK & ROS1 Inhibition: Blocks autophosphorylation of ALK and ALK-mediated phosphorylation of downstream proteins (STAT3, AKT, ERK1/2, S6), disrupting cancer cell signaling.
2. Multi-Kinase Targeting: Inhibits IGF-1R, FLT-3, and EGFR deletion/mutations, addressing resistance pathways.
3. Antitumor Activity: Demonstrates dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in preclinical studies.
4. Cellular Proliferation Control: Suppresses in-vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusions.

Clinical Applications & Indications

Bigatab 90 mg (Brigatinib) Tablet is indicated for:

• ALK-Positive NSCLC: Treatment of advanced or metastatic NSCLC in patients resistant to prior ALK inhibitors.
• ROS1-Positive NSCLC: Off-label use for ROS1-rearranged NSCLC based on clinical trial data.
• Second-Line Therapy: For patients progressing on crizotinib or other first-line TKIs.

Why Choose Bigatab 90 mg (Brigatinib) Tablet?

• Precision Targeting: Dual ALK/ROS1 inhibition with activity against resistance mutations.
• Broad-Spectrum Efficacy: Targets IGF-1R and FLT-3, overcoming tumor heterogeneity.
• Proven Survival Benefits: Clinical trials show improved progression-free survival (PFS) in ALK-positive NSCLC.
• Tolerability: Optimized dosing reduces severe adverse events compared to older TKIs.
• Global Quality: Manufactured under WHO-GMP standards by Eskayef Pharmaceuticals Ltd.

Manufacturer Credibility: Eskayef Pharmaceuticals Ltd.

Eskayef Pharmaceuticals Ltd., a flagship company of Bangladesh’s Transcom Group, has been a pioneer in oncology innovation since 1990. Acquired from SK&F (USA), Eskayef combines decades of expertise with cutting-edge technology to produce high-quality therapies like Bigatab 90 mg (Brigatinib) Tablet. Their WHO-GMP-certified facilities ensure compliance with international safety and efficacy standards, serving patients across Asia, Africa, and Europe. Learn more about their legacy at www.skfbd.com.

Supplier Profile: Onco Solution

Onco Solution is a global leader in oncology medicine distribution, ensuring access to life-saving treatments like Bigatab 90 mg (Brigatinib) Tablet. Key services include:

• Affordable Procurement: Competitive pricing for hospitals, clinics, and healthcare institutions.
• Global Logistics: Reliable delivery to 50+ countries, including low-resource regions.
• Expert Resources: Access to a directory of oncology specialists via www.oncosolution.com.

With core values of innovation, integrity, and compassion, Onco Solution bridges gaps in cancer care by prioritizing patient access and education.

Technical Specifications

• Active Ingredient: Brigatinib 90 mg
• Dosage Form: Film-coated oral tablet
• Storage: Store below 25°C in a dry, light-resistant container.
• Administration: Once daily, with or without food, as prescribed.
• Dosage Adjustment: Based on tolerability (e.g., 180 mg daily after initial 90 mg lead-in).

Patient-Centric Advantages

• Oral Convenience: Reduces hospital visits and supports home-based care.
• Dosing Flexibility: Adjustable regimens to manage side effects like nausea or fatigue.
• Improved Outcomes: Delays disease progression and enhances quality of life.

Clinical Trial Data & Efficacy

• ALTA-1L Trial: Demonstrated median PFS of 24 months vs. 11 months for crizotinib in ALK-positive NSCLC.
• Resistance Management: Effective against G1202R and other ALK resistance mutations.
• Intracranial Activity: High CNS penetration, reducing brain metastasis progression.

Safety Profile & Side Effects

• Common Side Effects: Nausea, diarrhea, fatigue, cough, and hypertension.
• Severe Reactions: Interstitial lung disease (ILD), bradycardia (monitor regularly).
• Contraindications: Hypersensitivity to brigatinib, severe hepatic impairment.

Global Accessibility & Partnerships

Through collaboration with Eskayef Pharmaceuticals Ltd., Onco Solution ensures Bigatab 90 mg (Brigatinib) Tablet reaches underserved regions, prioritizing:

• Affordability: Tiered pricing for low- and middle-income countries.
• Quality Assurance: Adherence to WHO-GMP, ISO, and FDA-equivalent standards.
• Education: Training programs for healthcare providers on TKI resistance management.

Ordering Information

Healthcare providers can procure Bigatab 90 mg (Brigatinib) Tablet through Onco Solution’s streamlined platform:

• Bulk Orders: Discounted rates for hospitals and oncology centers.
• Clinical Support: Access to dosing guidelines and adverse event management.
• Global Network: Connect with specialists via www.oncosolution.com.

Conclusion

Bigatab 90 mg (Brigatinib) Tablet is a transformative therapy for ALK/ROS1-positive NSCLC, offering precision targeting and robust clinical efficacy. Trust Eskayef Pharmaceuticals Ltd. for uncompromised quality and Onco Solution for global accessibility. For orders or clinical guidance, contact Onco Solution today.